Our Pipeline
Stream Neuroscience Innovation
Selective targeting of essential signaling molecules deep inside the cell
Promising Clinical Candidates
SN-2000
Inhibition of phosphodiesterase 4B (PDE4B) reduces the frequency of seizures in animal models of epilepsy and improves cognition in Phase 1/2 clinical trials in patients with neurological disorders. SN-2000 inhibits PDE4B and increases levels of cyclic adenosine monophosphate (cAMP), a crucial signaling molecule that helps regulate neuronal activity and communication. By boosting cAMP levels, PDE4 inhibitors can stabilize neuronal cell balance and make the brain less prone to seizures. Additionally, enhanced cAMP levels can improve efficiency and connectivity in the brain, thereby supporting cognitive functions such as learning, memory, and problem-solving. SN-2000 offers a new mechanism of action with potential to treat epileptic seizures and improve cognitive performance.
Phosphoinositide 3-kinase (PI3K) Discovery Program
The PI3K pathway is vital for cell growth, survival, and metabolism, and its dysregulation can lead to abnormal neuronal activity and cognitive impairments. By inhibiting PI3K, Stream Neuroscience hopes to reduce excessive signaling that contributes to epileptic seizures, thereby helping to stabilize neuronal activity and decrease seizure frequency. Additionally, PI3K inhibitors can promote neuroprotective effects, safeguarding neurons from damage and supporting their health. This stabilization of neuronal function can also enhance neural plasticity, enabling the brain to form new connections and improve cognitive abilities such as memory, learning, and higher cognitive functions. Stream Neuroscience’s PI3K drug discovery program hold promise as a therapeutic strategy to manage epilepsy and cognitive disorders by ensuring that neuronal signaling remains balanced and effective.
